Skip to main content
Retour
Watch Compare

Processa Pharmaceuticals, Inc.

Qualité des données : 83%
PCSA
Nasdaq Manufacturing Chemicals
2,77 €
▼ 0,20 € (-6,73%)
Cap. Boursière: 7,90 M
Prix
2,97 €
Cap. Boursière
7,90 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -11,39 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-227,18%
En dessous de la moyenne du secteur (-53,34%)
ROIC-185,10%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio3,76
Interest CoverageN/A

Valorisation

PE (TTM)
-0,58
Au-dessus de la moyenne du secteur (-1,47)
P/B Ratio1,35
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,6 -1,5
P/B 1,4 1,6
ROE % -227,2 -53,3
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

1 analyste
Aucune couverture d'analyste disponible

Estimations de Bénéfices

Aucune estimation prévisionnelle disponible

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q32025 -2,00 € -1,75 € +12,5%
Q22025 -5,75 € -6,25 € -8,7%
Q12025 -19,25 € -7,50 € +61,0%
Q42024 -23,00 € -18,50 € +19,6%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -13,56 M
ROE -227,18% ROA -172,06%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -11,39 M
ROIC -185,10% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,76
Interest Coverage N/A Asset Turnover N/A
Working Capital 4,84 M Tangible Book Value 5,83 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,58 Forward P/E N/A
P/B Ratio 1,35 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -144,11%
Market Cap 7,90 M Enterprise Value 1,59 M
Per Share
EPS (Diluted TTM) -10,36 Revenue / Share N/A
FCF / Share -4,28 OCF / Share -4,28
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 83,94%
SBC-Adj. FCF -12,27 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — 0,0 0,0
Net Income -13,56 M -11,85 M -11,12 M -27,42 M -11,43 M
EPS (Diluted) -10,36 -3,87 -8,48 — —
Gross Profit — — — — —
Operating Income -13,99 M -12,05 M -11,46 M -27,53 M -12,13 M
EBITDA — — — — —
R&D Expenses — — 5,80 M 11,49 M 6,88 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — 362,0
Income Tax — — — -530 611,0 -530 611,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,81 M 3,23 M 5,79 M 8,62 M 26,46 M
Total Liabilities 2,24 M 1,53 M 797 484,0 1,15 M 978 405,0
Shareholders' Equity 5,58 M 1,70 M 4,99 M 7,47 M 25,49 M
Total Debt — — — — —
Cash & Equivalents 5,54 M 1,19 M 4,71 M 6,50 M 16,50 M
Current Assets 5,67 M 1,87 M 5,63 M 8,39 M 18,33 M
Current Liabilities 2,24 M 1,53 M 730 579,0 998 556,0 971 020,0